Several other hepcidin-inducing agents are either enrolling PV patients to a phase II clinical trial (NCT05143957) or in planning stages, and the global, multicenter, randomized, placebo-controlled phase III trial (NCT05210790) is currently underway (Verstovsek et al., 2021) to further clarify the potential role of rusfertide in the management of patients with PV. Here, HAMP is linked to acquired polycythemia vera.